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UDP-glucuronosyltransferases (UGTs) form a multigenic family of membrane-bound
enzymes expressed in various tissues, including brain. They catalyze the formation of
β-D-glucuronides from structurally unrelated substances (drugs, other xenobiotics, as well
as endogenous compounds) by the linkage of glucuronic acid from the high energy
donor, UDP-α-D-glucuronic acid. In brain, UGTs actively participate to the overall protection
of the tissue against the intrusion of potentially harmful lipophilic substances that are
metabolized as hydrophilic glucuronides. These metabolites are generally inactive, except
for important pharmacologically glucuronides such as morphine-6-glucuronide. UGTs are
mainly expressed in endothelial cells and astrocytes of the blood brain barrier (BBB).
They are also associated to brain interfaces devoid of BBB, such as circumventricular
organ, pineal gland, pituitary gland and neuro-olfactory tissues. Beside their key-role as
a detoxication barrier, UGTs play a role in the steady-state of endogenous compounds, like
steroids or dopamine (DA) that participate to the function of the brain. UGT isoforms of
family 1A, 2A, 2B and 3A are expressed in brain tissues to various levels and are known
to present distinct but overlapping substrate specificity. The importance of these enzyme
species with regard to the formation of toxic, pharmacologically or physiologically relevant
glucuronides in the brain will be discussed.
Keywords: UDP-glucuronosyltransferases, blood-brain barrier, drug glucuronidation, detoxication barrier,
glucuronidation of endogenous compounds
THE UDP-GLUCURONOSYLTRANSFERASE FAMILY
UDP-glucuronosyltransferases (UGTs, EC 2.4.1.17) are a multi-
genic family of enzymes responsible for the glucuronidation reac-
tion, a main process of phase II xenobiotic biotransformation
(Mackenzie et al., 2005). Products of phase I reactions medi-
ated by P450-dependent monooxygenases are major substrates
of UGTs, although substances which possess a functional chem-
ical groups (hydroxyl-, phenyl, carboxylic acid, amines, thiols)
are readily glucuronidated. Some of these substances especially
hydroxylated or phenolic molecules can also be sulfated by sulfo-
transferases (SULTs). These enzymes compete with UGTs towards
the same substrates. UGTs as monooxygenases, are membrane-
bound enzymes. They are predominantly associated to the endo-
plasmic reticulum. If cytochromes P450 are expressed on the
cytosolic surface of the membranes, the UGTs are present on
the luminal side. Indeed intra-membrane co-localization and
interactions of cytochromes P450 and UGTs insure a topological
and functional coupling for an efficient stepwise drug biotrans-
formation (Ouzzine et al., 1999; Ishii et al., 2007).
Abbreviations: BBB, blood-brain barrier; CSF, cerebrospinal fluid;
DA, dopamine; 5-HT, 5-hydroxytryptamine; OB, olfactory bulb; OM,
olfactory mucosa; OS, olfactory system; UGT, Uridine-diphosphate-
glucuronosyltransferase.
UGTs are glycosyltransferases that catalyze the covalent
binding of glucuronic acid from the high energy donor, UDP-
αD-glucuronic acid on structurally related substances with a
functionalized nucleophilic group, leading to the formation of
water soluble β-glucuronides and UDP (Figure 1). The reac-
tion is believed to occur according to a second order nucle-
ophilic substitution (SN2) involving an amino acid base catalyst
(Magdalou et al., 2010). The main characteristic of UGTs is
their potency to glucuronidate a large array of structurally unre-
lated substances. They play a major role in the detoxication of
xenobiotics, including drugs and environmental substances, as
well as in the metabolism of endogenous compounds (biliru-
bin, steroid hormones, bile acids, fatty acids) (Rowland et al.,
2013). As such, they efficiently contribute to the protection of the
organism against hazardous chemicals, and regulate the activity
of several endogenous mediators involved in cell growth and
differentiation. Many therapeutic classes of drugs, some of them
targeting brain tissues, such as analgesics, anticonvulsants or
antipsychotics are UGT substrates (de Leon, 2003). UGTs are
also involved in the glucuronidation of endogenous compounds.
Particularly, the monoamine neurotransmitters, dopamine (DA)
and serotonin (5-hydroxytryptamine, 5-HT) are substrates of
UGTs which may play a regulating role in their physiological
function and implication in brain disorders (Suominen et al.,
2013).
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FIGURE 1 | Mechanism of the glucuronidation reaction catalyzed
by UDP-glucuronosyltransferases (UGT). Glucuronidation is a
bi-substrate reaction which requires an aglycone (for example, a
phenol) and a high energy glucuronic acid donor, UDP-α-D-glucuronic
acid, which is the common substrate to all UGT isoforms. The reaction
leads to the release of UDP and formation of a β-D-glucuronide. UGT
belongs to the inverting glycosyltransferase family which utilizes a
direct SN2-like mechanism involving a base (B) catalyst. Structurally
unrelated substances, brain transmitters and drugs against brain
disorders that are UGT substrates are shown: 1, serotonin; 2,
dopamine; 3, morphine; 4, valproic acid; 5, oxazepam; 6, lamotrigine; 7,
apomorphine; 8, ethanol.
This powerful detoxication barrier is due to the expression
in hepatic and extrahepatic tissues of several isoforms exhibit-
ing distinct but overlapping substrate specificity. In human up
to 22 UGT isoforms have been identified to date belonging
to 1A, 2A, 2B, 3A and 8A subfamilies, based on a 29 amino
acids conserved signature involved in the binding site for the
common substrate, UDP-glucuronic acid (Rowland et al., 2013).
Among these families, UGT1A, 2A and 2B are particularly
active in xenobiotic biotransformation. Interestingly, the UGT
isoforms exhibit tissue specificity in terms of isoform present
and level of expression. If liver contains the greatest amount
and variety of UGT isoforms, other organs, such as kidney
or the intestinal tract are known to express several isoforms
in significant amount (Court et al., 2012; Harbourt et al.,
2012).
UGT has also been found in brain and associated tissues.
A glucuronidation activity has been reported upon incubation
of microsomes from total brain of rat with xenobiotics and
endogenous compounds known to be substrates of the enzyme
(Suleman et al., 1993). This activity was much lower than that
found in liver or in other extra-hepatic organs. These enzymes
were progressively characterized at a protein and gene levels
using immunohistochemistry (Martinasevic et al., 1998) and PCR
techniques (Suleman et al., 1998), thus allowing a precise iden-
tification of the isoforms and their localization within the brain
tissues.
In the brain, despite their low level of expression, UGTs
participate, in cooperation with the other drug metabolizing
enzymes and the various ABC efflux transporters, to a metabolic
barrier which prevents efficiently the organ from the intrusion of
xenobiotics. Particularly, the blood brain barrier (BBB) and the
associated cells, such as the endothelial cells, play a critical role on
the cerebral homeostasis. The nasal cavity which affords a direct
route of entry for xenobiotics to the brain contains specific UGTs
isoform that are highly expressed in the olfactory tissue. In this
condition, variations of UGT expression by genetic (polymor-
phism), environmental (induction or repression), pathophysio-
logical factors or during ontogenesis and perinatal development
will affect the permeability and the metabolic function of this
barrier prone to potential toxic effects.
This review is focused on the importance of UGT in brain
function. Although if, in terms of drug metabolism, the relatively
small level of expression of these enzymes in the brain areas
would have a minor impact on the overall glucuronidation of
xenobiotics, it surely can have a major effect when protecting
locally a specific cerebral cell from the neurotoxicity of substances
which enter the brain. In terms of brain homeostasis, UGTs play a
subtle role in the fine tuning of the concentration of endogenous
neurotransmitters, ligands of receptors, or in the modulation of
the pharmacological effects of brain-directed drugs. The presence
of brain specific UGT isoforms highlights the importance of this
family of enzymes in this process.
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A LIMITED NUMBER OF UGTs ARE EXPRESSED IN THE
BLOOD-BRAIN BARRIER
The drug transporters and drug metabolizing enzymes that
are present in the BBB prevent access to the brain of some
lipid-soluble drugs and potentially toxic substances. It has been
shown, several years ago, that rat brain microsomes exhibit
high glucuronidation activity towards the reference substrate,
1-naphthol (Ghersi-Egea et al., 1987). This glucuronidation
activity was found to be rather low in human brain. Interestingly,
the 1-naphthol activity was also present in rat brain microvessels
(Ghersi-Egea et al., 1988), indicating the capacity of endothelial
cells to metabolize this compound and to participate to the
protection of the brain toward this substance and related toxic
compounds. The 1-naphthol activity was attributed to the
UGT isoform 1A6 (UGT1A6) as it has been demonstrated that
other phenolic substrates conjugated by this isoform were also
metabolized in brain (Suleman et al., 1993). At cellular level, the
1-naphthol UGT1A6 activity was 10-fold higher in astrocytes,
as compared with neurons and endothelial cerebrovascular cells
(Suleman et al., 1998). Investigation of the expression of UGT1A6
in brain has been carried out by several authors (Martinasevic
et al., 1998; Suleman et al., 1998). The expression of UGT1A6
was detected in rat astrocytes, neurone homogenates and brain
microsomes by immunoblotting and by reverse transcriptase-
polymerase chain reaction (RT-PCR). The presence of UGT1A6
in neuronal cells, especially the pyramidal cells of the cortex and
the granular cells in the cerebellum was further confirmed by
immunohistochemical localization of UGT1A6 using specific
antibodies (Martinasevic et al., 1998). However, this study did not
support the presence of UGT1A6 in the microvasculature of the
rat brain as previously suggested. Similarly, investigation of the
expression of UGTs in human brain microvessels did not reveal
the presence of UGT1A6 (Shawahna et al., 2011), suggesting that
this isoform was not expressed or very weakly expressed in human
brain microvessels compared to rat. In line with this, it has been
shown that UGT-mediated metabolism of 1-naphthol was less
prominent in human brain compared to rat brain, suggesting
that species differences may exist (Ghersi-Egea et al., 1993).
In addition to UGT1A6, the presence of UGT1A7, an isoform
known to glucuronidate benzo(a)pyrene hydroxylated metabo-
lites was detected by RT-PCR in rat astrocytes (Gradinaru et al.,
2012). As UGT1A6, the mRNA expression of this UGT isoform is
inducible by xenobiotics (Kobayashi et al., 1998). Among UGT1A
isoforms, UGT1A1 was shown to be expressed in rat cerebellum
at the mRNA level (Shelby et al., 2003). However glucuronida-
tion activity towards bilirubin, the main substrate of this UGT
isoform, has not been detected in rat brain, thus suggesting that
UGT1A1 was not present (Suleman et al., 1993).
Recently, the expression of UGT1A4 has been investigated in
brain. This isoform is known to catalyze the N-glucuronidation
of primary, secondary and tertiary amines, among those are anti-
convulsivants, tricyclic antidepressants and antipsychotics, such
as lamotrigine, doxepin or clozapine (Li et al., 2007; Kerdpin et al.,
2009). Immunobloting and glucuronidation activity using lamot-
rigine as a substrate indicated the presence of this UGT isoform in
human brain microvascular endothelial cells (Ghosh et al., 2013).
Analysis of the expression of UGT1A4 by immunohistochemistry
in brain from patients with epilepsy indicated high expression in
BBB endothelial cells and neurons with variable levels of UGT1A4
expression among the brain specimens analyzed. Endothelial cells
from brain microvessels of these patients showed high lamotrigine
glucuronidation activity compared to cells from non-pathological
brain (Ghosh et al., 2013), suggesting a role in the drug-resistant
epileptic brain. Although preliminary, these results emphasize the
potential importance of the UGT1A4 isoform in the biotransfor-
mation of psychiatric drugs in brain.
On the other hand, the UGT2B7 isoform catalyzes the glu-
curonidation of morphine to 3-O- and 6-O-glucuronide, the
latter metabolite presenting a higher analgesic potency than mor-
phine (Gong et al., 1991; Figure 2). It has been shown that
morphine-6-O-glucuronide exhibited a slow transport across the
BBB compared to morphine (Bouw et al., 2001), therefore the
presence of UGT2B7 in brain may lead to local formation of
morphine-6-O-glucuronide that can exert its analgesic actions.
Investigation of the expression of UGT2B7 and of the forma-
tion of morphine glucuronides has been conducted in rat and
human brain. In rat brain, analysis of the glucuronidation activ-
ity towards morphine indicated the absence of formation of
morphine glucuronides (Suleman et al., 1993), suggesting that
UGT2B7 may not be expressed in rat brain at least at basal
levels. In contrast, the expression of UGT2B7 has been revealed
by RT-PCR in human cerebellum 1, whereas no expression of this
isoform was detected in brain cortex (King et al., 1999). Analysis
of the glucuronidation activity of microsomes from human brain
cortex towards morphine did not show any detectable activity
confirming the absence of UGT2B7 in brain cortex. Only a weak
activity was present in cerebellum 1. Noteworthy, Wahlström
et al. (1988) reported the presence of morphine glucuronidation
activity in human brain microsomes. However, this activity was
detectable in only 3 out of 19 brain samples analyzed, suggest-
ing large inter-individual variations in brain expression of this
isoform. A recent model of transgenic mouse expressing human
UGT2B7 has been developed showing a differential expression
FIGURE 2 | Glucuronidation of morphine by UGT2B7 in human. The
reaction occurs on the two hydroxyl groups at positions 3 and 6 of
morphine, and leads to the formation of 3-, and 6-glucuronides which
present different pharmacological properties.
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and activity of the enzyme in several tissues including brain to
a lesser extent (Yueh et al., 2011). This animal model is a powerful
tool to decipher the role of UGT2B7 in vivo and to understand the
regulation mechanisms of its expression and activity under vari-
ous experimental conditions (in presence of various biologically
active compounds like drugs, toxics, hormones or in response to
potential UGT inhibitors).
Interestingly, Christen and Fent (2014) recently reported the
transcription profile of eight UGT genes in zebrafish tissues
(Ugt1a, Ugt1b, Ugt5a1, Ugt5a3, Ugt5a4, Ugt5a5, Ugt5c2, Ugt5c3).
They found they were significantly expressed in brain, especially
the UGT5a and 5c families. However their catalytic function and
implication in xenobiotic metabolism are not known yet. On the
other, in the antennae of the pest insect, Spodoptera littoralis,
Bozzolan et al. (2014) have characterized the expression of eleven
putative UGTs that were differently regulated by odorants. More-
over, the isoform UGT46A6 was up-regulated by the insecticide
deltamethrin. These data suggest a protective role of this enzyme
in this olfactory organ towards xenobiotics.
Altogether, among the different UGT isoforms characterized
so far in various tissues, it appears that only few of them are
expressed in mammal and human brain. The construction of an
anatomically comprehensive atlas of the adult human brain and
mouse transcriptome which is currently under way will undoubt-
edly bring additional information on the presence of other or
novel UGT isoforms (Lein et al., 2007; Sunkin and Hohmann,
2007).
ROLE OF GLUCURONIDATION IN THE METABOLISM OF
NEUROTRANSMITTERS
DOPAMINE AND SEROTONIN CONJUGATION IN BRAIN
DA and serotonin (5-hydroxytryptamine, 5-HT) are monoamine
neurotransmitters. Their homeostasis in central and peripheral
nervous system is important for many physiological processes
as well as in pathological situations (Meiser et al., 2013). The
function of DA has been linked to the regulation of motoric
movements. The age-related Parkinson’s disease that coincides
with the degeneration of dopaminergic neurons within the sub-
stantia nigra is associated with typical motor symptoms such as
rigidity, tremor or bradykinesia. The discovery that Parkinson’s
disease was associated with neostrial DA depletion (Ehringer
and Hornykiewicz, 1960) led to the first treatment with L-3,4-
dihydrophenelylalanine (DOPA, levodopa), which is still in use
today. Schizophrenia and depression are other diseases linked to
DA deregulation (Heinz and Schlagenhauf, 2010), and attention
deficit hyperactivity disorder (ADHD) has been recently con-
nected to deficient DA signaling (Tripp and Wickens, 2012). 5-
HT is involved in many physiological functions such as body
temperature regulation, blood pressure, perception of pain, sleep-
wake cycles, and pathological processes including depression and
anxiety (Berger et al., 2009).
Upon neuronal excitation, DA is released into the synaptic
cleft for signal transduction. DA signaling stops by reimport
to the synaptic neuron and recycling, or degradation
following uptake by glial cells. DA is primarily metabolized
by oxidative deamination by monoamine oxidase (MAO)
and aldehyde dehydrogenase-catalyzed reactions to 3,4-
dihydrophenylacetic acid (DOPAC; Figure 3). DOPAC can
be further metabolized to homovanillic acid (HVA) by catechol-
O-methyltransferases (COMT). 5-HT is metabolized by MAO
and aldehyde dehydrogenase to 5-hydroxyindoleacetic acid
(5-HIAA; Figure 3). Both DA and 5HT and their respective
metabolites can undergo conjugation with glucuronic acid or
sulfonate mediated by UGTs and SULTs respectively, that occurs
in both central nervous system and periphery. In the brain, phase
I metabolites of DA i.e., DPAC and HVA, which are linked to the
functional activity of dopaminergic neurons are predominant.
However, in rat, mouse and human cerebrospinal fluid (CSF)
that is assumed to reflect the metabolism of neurotransmitters,
DA-glucuronide and sulfate conjugates have been found (Wang
et al., 1983; Tyce et al., 1986; Uutela et al., 2009a). Due to the
lack of commercially available standards, most conjugates in
human, and animal CSF or brain samples have been analyzed
after acid or enzymatic hydrolysis (Swahn and Wiesel, 1976).
In addition, several studies report the detection of conjugates
but do not specify the type of conjugate (Gordon et al., 1976;
Tyce et al., 1985) leading to ambiguous results. However, in rat
CSF, DA glucuronide was found predominant over DA-sulfate
and free DA, suggesting that glucuronidation was an important
metabolic pathway for DA of central origin (Wang et al., 1983).
DA-glucuronide was also detected in human CSF samples
following β-glucuronidase analysis (Tyce et al., 1986). The
presence of intact glucuronide as the major DA conjugate was
recently confirmed in rat and mouse brain microdialysates using
liquid chromatography tandem mass spectrometry (LC-MS/MS;
Uutela et al., 2009a). LC-MS/MS also detected 5-HT-glucuronides
at concentration 2-times than HT itself (Uutela et al., 2009b).
Altogether, the results indicated that in rat, neurotransmitters
are glucuronidated whereas their phase I metabolites are sulfated
(Uutela et al., 2009b). In human, early studies identified sulfate
conjugates of DA and 5-HT (Ratge et al., 1985; Tyce et al.,
1986) and glucuronide conjugate of DA in CSF. Glucuronide
conjugates of HVA, DOPAC and 5-HIAA and DOPAC sulfate
were detected in a caudate nucleus human sample although HVA
and 5-HIAA occurred predominantly as free metabolites (Swahn
and Wiesel, 1976). Intact 5-HT and HVA-glucuronides were
detected in human brain samples. However, no glucuronides
were detected in CSF samples. These recent results using a direct
UPLC-MS-MS method clearly indicate that sulfate conjugation
of neurotransmitters predominates over glucuronidation in the
human brain (Suominen et al., 2013).
UGT ISOFORMS INVOLVED IN DOPAMINE AND SEROTONIN
GLUCURONIDATION
Among 22 recombinant human UGTs, only UGT1A10 was found
to catalyze DA glucuronidation at substantial rate although with
a low affinity, leading to the formation of both 4-O- and 3-O-
glucuronide (Itäaho et al., 2009). Very low activity was detected
for UGTs 1A6, 2A1, 2A3, 2B7, 2B11 and 2B17. However, no
expression could be detected in human brain that could be
responsible for DA-glucuronide formation (King et al., 1999;
Itäaho et al., 2009). UGT1A10 was also the most active human
UGT in the formation of HVA-O-glucuronide whereas UG2A1
conjugated HVA at the carboxyl-group (Suominen et al., 2013).
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FIGURE 3 | Major metabolic pathway of serotonin
(5-hydroxytryptamine) and dopamine (DA) to Phase I and Phase II
metabolites (sulfate, S; glucuronide, G). Monoamine oxidase (MAO),
aldehyde dehydrogenase (ADH) 3,4-dihydrophenylacetic acid (DOPAC),
homovanillic acid (HVA), catechol-O-methyltransferases (COMT),
5-hydroxyindoleacetic acid (5-HIAA). Main sulfo- and glucuronoconjugate
found in human brain are indicated by arrows (data from Suominen et al.,
2013).
5-HT has been shown to be a substrate for UGT1A6 and was
proposed as a probe for this isoform (King et al., 1999). However,
we were not able to detect 5-HT glucuronidation in recombinant
cells expressing UGT1A6 in our laboratory (Fournel-Gigleux
et al., 1991). This may be due to the low efficiency of UGT1A6
towards its substrate compared to the reference compound,
1-naphtol (8-fold). UGT2B7 also exhibited very low activity
towards this substrate (King et al., 1999). The recombinant
mouse Ugt1a6a and Ugt1a6b isoforms were able to glucuronidate
5-HT with approximately same efficiencies (Uchihashi et al.,
2013). Since Ugt1a6a was predominantly expressed in mouse
brain, especially in the hippocampus, it was proposed that this
isoform is involved in the glucuronidation 5-HT in mouse brain.
Altogether, monoamine neurotransmitters and their metabolites
appear as poor substrates for recombinant human UGTs.
PHYSIOLOGICAL SIGNIFICANCE OF NEUROTRANSMITTERS
GLUCURONIDATION IN BRAIN
The main excretion products of DA found in human urine are
HVA, DOPAC, their sulfates and glucuronides, as well as DA
conjugates. In the brain, DA and 5-HT conjugation seems to
play only minor roles as in microdialysates, the main metabolites
are DOPAC and HVA for DA, and HIAA for 5-HT. Whether
glucuronidation is more or less important than sulfoconjuga-
tion is also questionable. Reports concerning the ratio of con-
jugated to non-conjugated metabolites and the ratio of sulfates
to glucuronides are variable. In mouse and rat, there are mainly
glucuronides over sulfates, for example, the concentration of 5-
HT-glucuronide was about 2.5-times higher than of free 5-HT
in rat brain microdialysates (Uutela et al., 2009b). On the other
hand, in human CSF, 5-HIAA-sulfate and DA-3-O-sulfate were
the predominant conjugates of 5-HIAA and DA respectively, no
glucuronides were detected (Suominen et al., 2013). Quantitative
results of DA and 5-HT metabolism indicate that sulfation is a
more important phase II metabolism in human brain. Overall,
the low glucuronidation activities towards DA and 5-HT, together
with the UGT expression level found in brain tissues, and the poor
efficiency of recombinant UGTs are indicative of a minor role of
glucuronidation in DA and serotonin metabolism. The role of
neurotransmitters conjugates in the brain remains to be clarified.
Whether they exert neurotoxic or neuroprotective properties or
have pharmacological impact on brain function, especially in the
case of sulfate conjugates is an interesting question that requires
further investigation.
ROLE OF UGT IN THE GLUCURONIDATION OF XENOBIOTICS
IN BRAIN
As indicated above, several lines of evidence highlight the impor-
tant role of UGT in brain homeostasis and neuronal protection
against the entry of drugs and other xenobiotics. In order to
illustrate this part, the glucuronidation of several xenobiotics in
brain is reported.
MORPHINE GLUCURONIDATION IN BRAIN
Morphine is one of the most potent and widely used opioid
derivatives for acute or chronic pain relief. Once absorbed and
distributed in blood flow, morphine is efficiently transferred
across the BBB of rodent brain (Kalvass et al., 2007; Boström
et al., 2008). The diffusion process varies according to the age or
to the injected morphine dose (Bhargava et al., 1993). Interest-
ingly, morphine can also be produced in situ in several tissues,
including brain, from endogenous precursors such as tyramine
and DA, (Laux-Biehlmann et al., 2013). De novo morphine syn-
thesis from DA or L-tyrosine has been described in mammalian
brain (Stefano et al., 2008) or human neuronal catecholamine-
producing cell line SH-SY5Y (Poeaknapo, 2005; Muller et al.,
2008). This biosynthetic pathway has been investigated by the
use of potential precursors or deficient animal models such as
DA-deficient mice. The results showed the requirement of DA
for morphine formation (Neri et al., 2008). It has been strongly
suggested that the presence of endogenous morphine in several
tissues could be involved in pain modulation in response to
various stimulations as stress, immune responses (Charron et al.,
2011) or sepsis (Glattard et al., 2010). The recent (co)localization
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of morphine and morphine-like compounds in mouse brain areas
not usually known to be involved in brain responses to pain brings
new questionings about the potential other(s) role(s) of morphine
and its derivatives (beside antalgic activity) in mammalian brain
(Laux et al., 2011).
Morphine is mostly metabolized by glucuronidation leading
to the production of two metabolites: the pharmacologically
inactive and major metabolite, morphine-3-β-D-glucuronide
(M3G) and the highly active but minor metabolite, morphine-6-
β-D glucuronide (M6G; Figure 2; Nagano et al., 2000; De
Gregori et al., 2012). A recent work reported the formation of
M3G and M6G in primary cultures of neonatal rat microglia
in presence of micromolar concentrations of morphine (Togna
et al., 2013). The authors suggested that morphine glucuronides
found in the CSF after morphine administration was in part
formed in situ. As indicated before, among the UGT isoforms
expressed in brain, UGT2B7 has been reported to glucuronidate
morphine in several animal species and in humans (Court et al.,
2003; Stone et al., 2003; Wong et al., 2006; Abildskov et al., 2010;
Figure 2). Although UGT2B7 supported metabolism in liver is
well described, the contribution of this UGT isoform in brain
is still poorly documented and remains to be investigated in terms
of pharmacological effects and potential consequences on brain
homeostasis.
RESVERATROL GLUCURONIDATION IN BRAIN
Resveratrol (trans-3, 5, 4′-trihydroxystilbene) is a natural
polyphenol produced by plants more particularly present in
grapes and in high concentration in red wine. This compound
has been regarded as a bioactive agent with possible beneficial
effects in health. Its anti-oxidant properties may have thera-
peutic applications for cardiovascular or brain diseases. It has
also been suggested that resveratrol could maintain neuronal
energy homeostasis in relation to glutamate receptors and/or
ions channels (Quincozes-Santos et al., 2014). Its neuroprotective
effects have been shown in ischemia prevention in brain after a
brief resveratrol pretreatment (Raval et al., 2008). Dasgupta and
Milbrandt (2007) showed that resveratrol could activate the AMP-
activated kinase (AMPK) in mouse neuroblastoma cell lines and
in rat primary cultures of neurons, promoting neurite growth.
These data strongly suggest that the neuroprotective effects of
resveratrol could be mediated by the activation of AMPK in
neurons (Dasgupta and Milbrandt, 2007).
Bioavailability of resveratrol is limited by its extensive bio-
transformation via sulfo- and glucuronidation pathways in
rodents and humans (Iwuchukwu et al., 2012). This metabolism
mainly occurs in kidney and in liver, and is low in rat brain
(Juan et al., 2010). Resveratrol biotransformation leads to the
production of various monoconjugated metabolites as 3- and 4′
monosulfates and 3- and 4′-monoglucuronides (Aumont et al.,
2001; Sharan et al., 2012) that are excreted in urine. Previous stud-
ies showed that resveratrol was mainly metabolized by UGTs in
rat brain homogenates, astrocyte primary cultures and olfactory
mucosa (OM). Interestingly, only resveratrol 3-O-glucuronide
has been produced in these cellular extracts whereas neither
resveratrol 4-O′-glucuronide, nor sulfated conjugates could be
detected in the same experimental conditions (Sabolovic et al.,
2007). However the UGT isoforms involved in these reactions
have not been identified, even if UGT1A6 and UGT2B7 are known
to glucuronidate resveratrol. Finally, using glioblastoma cell lines
from rat and human, Sun et al. (2013) showed that mainly
glucuronides were formed in rat, whereas sulfate metabolites were
produced in human cellular extract.
ETHANOL GLUCURONIDATION IN BRAIN
Ethanol is primarily oxidized in the liver and also in BBB.
Glucuronidation has been recently described as a novel ethanol
biotransformation pathway, with the characterization of an ethyl-
glucuronide metabolite (Walsham and Sherwood, 2012). This
metabolite represents 0.02–0.06% of the ethanol intake (Janda
et al., 2002). Several recombinant UGT isoforms including
UGT1A6 and UGT2B7 have been shown to catalyze the formation
of ethylglucuronide (Schwab and Skopp, 2014). The ethylglu-
curonide presents a much longer half-life than ethanol itself
and its relevance in clinical diagnostics has been suggested as
a marker of alcohol consumption (Rainio et al., 2014). In line,
previous studies have measured high concentrations of ethylglu-
curonide in CSF and brain of patients who died of acute alcohol
intoxication (Wurst et al., 1999). The molecular mechanism for
ethylglucuronide action has not been precisely described but it
has been recently suggested that it could induce the toll-like
receptor 4 signaling pathway leading to pain enhancement (Lewis
et al., 2013). Ethylglucuronide formation exemplifies the biolog-
ical importance of glucuronidation in brain. The mechanism of
formation and action requires further investigation.
POLYCHLORINATED BIPHENYL GLUCURONIDATION IN BRAIN
Brain can also be a potential target for environmental pollu-
tants. Polychlorinated biphenyls (PCB), which are highly toxic
molecules present in persistent organic pollutants such as fumes
and cigarette smoke have been described to be the cause of
neurological adverse effects for years. A recent work showed a
delay in the neuronal migration in fetal cortex following a prenatal
exposure of a PCB mixture (Naveau et al., 2014). However,
the mechanism underlying PCB toxicity in brain has not been
clearly described yet. It has been hypothesized that the PCB
neuronal deleterious effects could be related in part with the
formation of one of their phase I metabolites, the hydroxyl-PCB
produced by cytochrome P450 monooxygenases (Fonnum and
Mariussen, 2009). This metabolite is glucuronidated in vitro by
the rat UGT1A6 isoform which is expressed in brain (Daidoji
et al., 2005). Taken together, these results strongly suggest that this
UGT could be involved in hydroxyl-PCB glucuronidation in brain
which could represent a PCB detoxification pathway and prevent
its neurotoxicity.
In conclusion to this part, brain tissue is able to glucuronidate
various xenobiotics which can cross the BBB. This reaction mainly
leads to the neutralization of their toxicity or pharmacological
activity. However, the potency of the brain to hydrolyze the
glucuronides once formed has not been extensively explored. This
reaction which is catalyzed by β-glucuronidases, leads back to
the parent compounds. The balance glucuronidation/hydrolysis
reaction must be taken into account to estimate the actual con-
centration of xenobiotics in the brain.
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FIGURE 4 | Schematic representation of bilirubin biliary elimination
pathway and neurotoxicity in a context of UGT1A1 defect. BBB, Blood
Brain Barrier; BIND, Bilirubin Induced Neurological Dysfunction; BMG,
bilirubin monoglucuronides; BDG, bilirubin diglucuronide; UGT,
UDP-glucuronosyltransferase.
THE BRAIN TOXICITY OF BILIRUBIN IS ASSOCIATED TO A
DEFECT IN BILIRUBIN GLUCURONIDATION IN THE LIVER
Bilirubin is a toxic product of heme catabolism of hemopro-
teins produced in high amount. Normal plasma concentration
of bilirubin has been measured between 2–10 mg/l in healthy
people, which results from a daily production of about 200–300
mg of bilirubin. Once produced, the main excretion/detoxication
pathway of the pigment is through glucuronidation supported by
the UGT1A1 isoform (Ohta et al., 2005). The reaction leads to the
production of bilirubin monoglucuronides (BMG) and bilirubin
diglucuronide (BDG) which are finally excreted into bile and feces
(Figure 4).
Indeed, when bilirubin is less metabolized, because of an
immature glucuronidation capacity, as in newborns for instance
(neonatal icterus), or in relation to UGT polymorphism (see
below), unbound (free) plasma bilirubin concentration increases.
The hydrophobicity of bilirubin explains its ability to efficiently
permeate the BBB by passive transport (diffusion), resulting in
its accumulation in brain where the molecule exerts its neu-
rotoxic effects (Gazzin et al., 2012; Figure 4). In this context,
glucuronidation of bilirubin in tissues could be regarded as a
regulation mechanism to control its diffusion through BBB, as
only free/unconjugated bilirubin can reach the brain (McDonagh,
2010). It has also been shown that high free bilirubin con-
centrations disrupt the integrity of human brain microvascular
endothelial cells in primary cultures or in monolayer cultured-
cell lines in terms of permeability and secreting activity. It has
been suggested that prolonged and high exposition to bilirubin
could cause brain endothelial cell injury by an oxidative stress-
mediated mechanism in relation to a loss in glutathione home-
ostasis, increase in nitrite oxide production and cytokine (IL6)
release (Palmela et al., 2011).
UGT1A1 is the only UGT described to date able to glu-
curonidate bilirubin. Therefore glucuronidation represents a
rate-limiting step for the metabolism and elimination of the
pigment. UGT1A1-mediated bilirubin conjugation has never
been detected in brain, meaning that the conjugation of bilirubin
in the other tissues, especially in the liver can be considered as
a metabolic barrier to prevent its diffusion into the brain and
thus to control its neurotoxicity. Recent studies on transgenic
mouse expressing the human UGT1A gene locus (encoding 9
UGT1A genes, including UGT1A1) have been conducted, show-
ing that about 8–10% of humanized UGT1A mice died from CNS
damages with neuroinflammation and reactive gliosis as a con-
sequence of neonatal hyperbilirubinemia (Fujiwara et al., 2010).
High serum bilirubin concentrations have been observed in these
transgenic animals in relation to limited UGT1A expression.
More precisely, a delayed UGT1A1 expression has been pointed
out, which explains hyberbilirubinemia and all the associated
pathological features including bilirubin-mediated neurotoxicity
(Chen et al., 2012).
The UGT1A1 gene is prone to an intense genetic variability
in the human population including mutations on the open read-
ing frame or in the promoter (TATA box) region leading to a
decrease or even to a complete loss of bilirubin glucuronidation.
Various pathological disorders have been described, such as the
frequent, although benign Gilbert’s syndrome (Strassburg et al.,
2008), or in contrast the rare but severe Crigler-Najjar syndromes
(Bartlett and Gourley, 2011). All these diseases are characterized
by moderate to high hyperbilirubinemia, respectively. A genetic
defect in UGT1A1 and thus in bilirubin glucuronidation leads to
high and potentially neurotoxic plasma bilirubin concentrations.
When the concentration of the free fraction of the molecule
exceeds the capacity of the UGT1A1 isoform, bilirubin becomes
neurotoxic crossing the BBB, diffusing in specific brain regions
(corpus striatum and hippocampus for instance) and inducing
irreversible neuronal damages such as kernicterus (Brito et al.,
2013).
In conclusion, bilirubin glucuronidation by UGT1A1 is a
prerequisite and a key- step for detoxication of the pigment.
Hepatic biotransformation of bilirubin by UGT1A1 controls its
neurotoxicity by preventing its brain uptake and slowing down its
BBB permeation, and finally by promoting its biliary excretion.
On the other hand, controlling bilirubin amount in blood flow by
increasing UGT1A1 expression seems to be an important strategy
to prevent its neurotoxicity.
UGT AND OLFACTORY TISSUES
In the previous sections, the important role of BBB and brain
UGTs in the context of brain protection against xenobiotics
has been discussed. However, since the last two decades, the
olfactory system (OS) has emerged as an alternate barrier struc-
ture preventing penetration of inhaled toxic molecules into the
brain. This assertion mainly relies on the early identification
of some tissue-specific UGTs (Lazard et al., 1990, 1991), and
cytochromes P-450 enzyme subfamilies (Nef et al., 1989; Zupko
et al., 1991), in bovine, rat, and also human olfactory neuro-
epithelium (Jedlitschky et al., 1999; Sneitz et al., 2009; Court
et al., 2012). Indeed, these enzymes, which were first predicted to
play important roles in chemoreception and especially in odorant
signal termination (Nef et al., 1989; Lazard et al., 1991), are now
ascertained as specific nasal xenobiotic metabolizing enzymes
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(Thiebaud et al., 2010; Xie et al., 2013). Nowadays, UGTs, due
to their potency to glucuronidate a wide range of unrelated
chemicals compounds, are considered as the main enzymes that
confer to OS its known role as a metabolic barrier against poten-
tially toxic inhaled substances. In mammals, OS consists in a
neurophysiologic system including the OM and the olfactory bulb
(OB) whose structures respectively allow generation, processing
and driving of afferent odorant signals to the olfactory cortex
(Mori et al., 2006). Since both OM and OB are able to express
UGTs (Leclerc et al., 2002), OS can be considered as a metabolic
defense structure against toxic airborne substances, in which OM
and OB respectively represent an early and a late barrier stage.
In this section, we will describe the UGTs isoforms which have
been clearly identified in OM and OB, and their activities and
roles in terms of brain protection against airborne substances
intrusion.
THE OLFACTORY MUCOSA AS AN EARLY LINE OF DEFENSE AGAINST
TOXIC INHALED SUBSTANCES
The expression pattern of UGTs in the OM tissue has been
investigated. Attention was first focused on the UGT2A1 isoform
previously called UGTolf since Lazard et al. (1991) demonstrated
that it was almost exclusively expressed in the olfactory tissue.
They also detected by in situ immunolocalization the presence of
UGT2A1 in the Bowman’s glands and in the apical pole of the
sustentacular cells on serial frozen sections of bovine olfactory
epithelium (Lazard et al., 1991). This result was later confirmed
by Jedlitschky et al. (1999) in the human olfactory epithelium.
By in situ mRNA localization and quantitative RT-PCR assays
on rat olfactory epithelium, Heydel et al. (2001) reported that
UGT2A1 mRNA was detectable in Bowman’s glands and susten-
tacular cells, and also in olfactory sensory neurons. These data
were confirmed by a proteomic approach by Mayer et al. (2008).
However, at a lesser extent, others UGT isoforms were also shown
to be expressed in OM. Thus, Leclerc et al. (2002) described the
presence of UGT1A6 mRNA in rats OM, although this latter
isoform was 400 to 4,000 times less expressed than UGT2A1.
Furthermore, high-throughput analysis of more than 6,000 cDNA
mouse sequences indicated the expression of UGT2A2, a splice
variant of UGT2A1, in neonatal OM whose glucuronidation
activity towards several different endo- and xenobiotic substrates
was similar to that of UGT2A1 (Strausberg et al., 2002; Sneitz
et al., 2009; Court et al., 2012).
UGT2A1 is, thus, widely expressed among the cells which
constitute the OM tissue. However, the expression of the UGT1A6
isoforms also contributes to the glucuronidation activity observed
in the OM tissue. What does this co-localization mean? A prelim-
inary answer would reside in the difference and complementarity
of substrate specificity of UGT2A1 compared to that of UGT1A6.
In one hand, UGT2A1 catalyzes mainly the glucuronidation of
most odorant compounds including numerous phenols deriva-
tives, aliphatic and monoterpenoid compounds, but also accepts
numerous steroids as endogenous substrates including testos-
terone, 5α-androstane-17β-ol-3-one or 5α-androstane-3α-17β-
diol (Jedlitschky et al., 1999). On the other hand, UGT1A6,
which is expressed in various tissues (Ouzzine et al., 1994;
Münzel et al., 1996), including brain (King et al., 1999) is mainly
involved in the glucuronidation of planar phenols (Tukey and
Strassburg, 2000), acetaminophen (Bock et al., 1987), serotonine
(Krishnaswamy et al., 2003, 2004), but also glucuronidates car-
cinogenic arylamines and aryl hydrocarbons (Gschaidmeier et al.,
1995). Moreover, UGT1A6 was recently shown to present a
significant affinity toward nonsteroidal anti-inflammatory drugs
and salicylate derivatives (Soikkeli et al., 2011). As expected,
the chemical structure of the substrates recognized by UGT2A1
differs from that for UGT1A6 suggesting that conjugation by
both enzymes allows widening the spectra of inhaled molecules
that could be glucuronidated. This is consistent with the role
of OM as metabolic structure preventing penetration of poten-
tially toxic inhaled substances inside the brain. However, this
assertion should be considered in the light of the recent studies
regarding the complex expression regulation of these enzymes.
Indeed, the expression level of UGT2A1 mRNA was shown to
be significantly higher than that of UGT1A6 mRNA in rat OM
but not in rat OB, indicating that olfactory UGT expression was
tissue-dependent (Leclerc et al., 2002). The same authors also
demonstrated that UGT2A1 and UGT1A6 expression in rat OM
were age-dependent. Furthermore, Buckley and Klaassen (2007)
showed that, in mice, female-predominant expression of UGT2A1
was observed in OM, while male-predominant expression of
UGT1A6 was rather observed in lung, suggesting that expression
of these OM UGTs could also be gender-dependent (Buckley and
Klaassen, 2007). Interestingly, Thiebaud et al. (2010) reported that
UGT2A1 and UGT1A6 did not share the same gene transcription
inducers in rat OM. In fact, UGT2A1 mRNA expression level was
up-regulated by dexamethasone (DM) whereas no modulation
effect of phenobarbital, Aroclor 1254, methylcholanthrene or
ethoxyquin upon the residual UGT2A1 mRNA expression level
was observed. Furthermore, these authors also showed that none
of these compounds could up-regulate the UGT1A6 mRNA resid-
ual expression. Several xenobiotic-response transcription factors
(XRTF) involved in the modulation of some UGTs expression in
rat OM have been identified. These XRTFs, including aryl hydro-
carbon receptor, nuclear factor E2-related factor 2, peroxisome
proliferator-activated receptor, pregnane X receptor, and gluco-
corticoid receptor, are known to mediate UGTs mRNAs expres-
sion upon addition of specific inducers in rat OM (Thiebaud
et al., 2010), but also in mouse liver and intestine (Buckley and
Klaassen, 2009). Thus, such an approach would allow: (i) to
decipher the molecular basis of the enzymatic response of OM
towards inhaled substances (ii) to highlight transcription factors
or metabolic partners which would be targeted in therapeutic
aims (Rowland et al., 2013). Besides its known role as a neurosen-
sory structure, OM can also be considered as a dynamic structure
capable to adapt the expression of its xenobiotic metabolizing
enzymes to terminate olfaction signal but also to eliminate toxic
inhaled compounds in the context of brain protection.
THE OLFACTORY BULB AS A LATE LINE OF DEFENSE AGAINST TOXIC
INHALED SUBSTANCES
OB is a second line of defense of OS since this structure was also
shown to express drug metabolizing enzymes, including UGTs
(Leininger et al., 1991). OB main role is to process the olfactory
signals received from olfactory sensory neurons to then ensure
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their transfer towards the olfactory cortex and towards other brain
areas including the amygdala, the hippocampus, the piriform
cortex, and the entorhinal cortex to mainly generate olfactory
information and odor memory (Johnson et al., 2000; Buck, 2005;
Mori et al., 2006; Zelano et al., 2009). Few groups attempted to
identify the UGTs that were specifically expressed in OB tissue,
and demonstrated the expression of the UGT2A1 and UGT1A6
isoforms. The expression was heterogeneously distributed among
the different cells of OB. By in situ hybridization analysis, Heydel
et al. (2001) successfully localized UGT2A1 mRNA expression
inside the granule cells and in a lesser extent in some mitral
cells whereas no signal was observed in the other layers of OB.
Unfortunately, no such exploration was made for UGT1A6.
UGT1A6 was identified as the main enzyme responsible for
the glucuronidation of 1-naphthol in rat OB (Gradinaru et al.,
1999). The activity was age-dependent and a significant increase
of UGT1A6 mRNA expression level was observed in OB for rats
older than 3 months (Leclerc et al., 2002). Interestingly, UGT2A1
was expressed in rat OB, although at a less amount than in
OM. mRNA expression level increased for rats from 1-day up to
3-months-old, then decreased thereafter (Leclerc et al., 2002).
These data are important as they suggest that OB possesses the
same enzymatic potency as OM against toxic inhaled substances.
These data also suggest that, as a function of age, UGT1A6 likely
plays a greater role in the glucuronidation activity when com-
pared to UGT2A1. Interestingly measurement of glucuronidation
activity toward a series of structurally unrelated hydroxylated
substances including odorants and phenols suggested that other
UGT isoforms may be expressed in rat OB. To better understand
how OB exerts its detoxification role to ensure brain protection,
further exploration regarding the identification of such hypothet-
ical isoforms should be undertaken.
The results acquired during these last two decades undoubt-
edly indicates that, more than a complex signal processing struc-
ture, OB acts as an additional line of defense against toxic
substances that would target the cerebral tissue thanks to the
presence of UGT2A1 and UGT1A6 enzymes. Moreover, this sub-
structure of the OS has to be considered as a “late” line of defense,
because OB is already recognized as a part of the forebrain and
thus belongs to the cerebral tissue.
CONCLUSIONS
Compared to other organs, brain tissues are characterized by a
qualitatively and quantitatively low expression of UGTs. Only
few isoforms are present which are heterogeneously distributed
among the several cells constituting the different brain areas.
Beside their significant participation to the overall protection of
the brain against the entry of xenobiotics, including pollutants
present in our environment, these enzyme species are special-
ized toward the biotransformation of brain-directed substances,
including metabolism of neurotransmitters chemically related to
DA, or antipsychotic drugs. However, the contribution of UGTs
expressed in liver or in gastro-intestinal tract in the protection
of the brain against drugs and other xenobiotics has to be taken
into account. By actively eliminating these substances from the
body, they decrease the risk of their entry into the brain. On the
other hand, a better knowledge on the UGTs, and other drug
metabolizing enzymes and transporters in the BBB and olfactory
tissues is a prerequisite to design and target pharmacological com-
pounds toward brain able to bypass these physiological barriers.
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